Press Room

DDL 2017

Start
Wednesday, December 06, 2017 - 00:00
End
Wednesday, December 06, 2017 - 00:00
Location: Scotland, UK
Booth Number: 420
drug product manufacturing | Hovione

Hovione will be attending DDL 2017 in Edinburgh, Scotland. 

Hovione is present with a booth where our experts and the business team can explain about our services and technologies in the inhalation area. Also, 4 posters will be presented, covering the areas of Particle Engineering, Formulation Development and Advanced Analytical Characterization. Hovione Technology also attended the conference presenting the company portfolio of DPI devices.

 

HOVIONE POSTERS

Dissolution of Orally Inhaled Drugs using DissolvIt®Influence of a Newly Designed Pre-Separator for Particle Collection
Beatriz NoriegaEunice Costa, Filipa Maia

Spray Dried Composite Particles: Formulation and Process Parameters, Effect of two API Concentrations and Stability Assessment
Maria Palha, Raquel Barros, Cláudia Moura, Sofia Silva, Sara Cardoso, Eunice Costa, Márcio Temtem

 

If you would like to discuss with us your projects and to find how Hovione can help, schedule a meeting with us.
Marcel Hogerheide will be pleased to meet you.

Marcel Hogerheide  | Hovione

Marcel Hogerheide

Head of Account Management & Business Development

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025